Topical Timolol for the Treatment of Benign Vascular Periocular Lesions

This study has been withdrawn prior to enrollment.

(Unknown, PI has left the institution. There was no enrollment.)

Sponsor:

Information provided by (Responsible Party):

Loyola University

ClinicalTrials.gov Identifier:

NCT01250457

First received: November 29, 2010

Last updated: October 29, 2012

Last verified: October 2012

History of Changes

Purpose

The purpose of this research is to find out if the use of topical timolol 0.5% solution applied twice daily will help to shrink rosacea lesions around the eye.

Condition	Intervention	Phase
Benign Vascular Periocular Lesions	Drug: topical Timolol	Phase 4


Study Type:	Interventional
Study Design:	Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Topical Timolol for the Treatment of Benign Vascular Periocular Lesions

Resource links provided by NLM:

Drug Information available for: Timolol Timolol maleate

U.S. FDA Resources

Further study details as provided by Loyola University:

Primary Outcome Measures:

lesion resolution [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Pre-treatment and post-treatment lesion size will then be compared to determine whether twice-daily topical application of timolol 0.5% solution alters the morphometry of benign vascular periocular lesions.


Enrollment:	0
Study Start Date:	June 2010
Study Completion Date:	July 2012
Primary Completion Date:	July 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Topical timolol topical Timolol 0.5% solution applied twice daily	Drug: topical Timolol topical Timolol 0.5% solution applied twice daily Other Name: Timoptic

Detailed Description:

Benign vascular tumors of the eyelid are common causes of ocular morbidity. Capillary hemangiomas in children cause refractive and occlusive amblyopia. In adults, Rosacea-associated eyelid telangiectasis and sclerosis can result in keratitis and corneal neovascularization. Corticosteroid therapy of benign vascular lesions risks sight-threatening complications including central retinal artery occlusion and significant systemic morbidity. Alternatively, oral and intravenous beta-blockers have been reported to induce regression of benign vascular lesions. One recent report documented efficacy of topical timolol in treating a large capillary hemangioma of the eyelid in a child. Topical application reduces systemic side effects of beta-blockers including bradycardia, hypotension, heart block, and bronchospasm. This one-year prospective case-control series will investigate whether topical Timolol 0.5% solution applied twice daily causes significant regression of benign vascular periocular lesions.

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Presence of a benign vascular periocular lesion

Exclusion Criteria:

Allergy to timolol or beta-blocker class of drugs
Lesion characteristics concerning for atypia or malignancy including madarosis, ulceration, and recurrence after previous surgery.
Intraocular Pressure less than 10 mm Hg

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01250457

Locations


United States, Illinois
Loyola University Medical Center
Maywood, Illinois, United States, 60153

Sponsors and Collaborators

Loyola University

Investigators


Principal Investigator:	David Yoo, MD	Loyola University

More Information

No publications provided


Responsible Party:	Loyola University
ClinicalTrials.gov Identifier:	NCT01250457 History of Changes
Other Study ID Numbers:	202688
Study First Received:	November 29, 2010
Last Updated:	October 29, 2012
Health Authority:	United States: Institutional Review Board

Additional relevant MeSH terms:


Timolol Adrenergic Agents Adrenergic Antagonists Adrenergic beta-Antagonists Anti-Arrhythmia Agents Antihypertensive Agents	Cardiovascular Agents Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Pharmacologic Actions Physiological Effects of Drugs Therapeutic Uses

ClinicalTrials.gov processed this record on February 27, 2015

To Top